logo
Missile on display in central Massachusetts park for decades moved to new home

Missile on display in central Massachusetts park for decades moved to new home

CBS News3 days ago
A missile that has stood tall in an Auburn, Massachusetts park for more than 40 years has moved to a new home.
Crews used a crane to get the Polaris missile off the ground at Goddard Park near the Auburn Mall on Friday so it could be moved to the EcoTarium, a science museum in Worcester.
Goddard Park is named after Worcester native Robert Goddard, who is considered the father of modern rocketry.
The Auburn Select Board voted in July to donate the missile to the EcoTarium, which had expressed an interest in restoring it and using it for educational purposes as part of the museum's space exhibit.
Auburn town manager Dori Vecchio said at the meeting that the missile was "rotted from within" and there were concerns that it might fall down.
"We had anticipated originally refurbishing the missile rocket at Goddard Park," she said. "Unfortunately it has deteriorated to the point where it doesn't make any sense."
The fire department said the missile had a large split in the metal running down its side and "has become home to Bee Colonies from all over Central MA."
Goddard, a physicist who studied at WPI and Clark University, launched the first liquid-fueled rocket from Auburn in 1926. A NASA biography says Goddard's achievement was a key contribution to future space flight and "as significant to history as that of the Wright brothers at Kitty Hawk."
Polaris missiles were the U.S. military's first submarine-based nuclear missiles. The tourism website RoadsideAmerica.com notes that "Although visually satisfying, the missile is, awkwardly, a solid-fueled rocket," unlike Goddard's invention.
Vecchio said the town aims to make Goddard Park "more related to Dr. Robert Goddard" as Auburn prepares to mark the centennial of Goddard's launch next year.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Advancing rare disease trials by overcoming patient recruitment challenges
Advancing rare disease trials by overcoming patient recruitment challenges

Yahoo

time2 hours ago

  • Yahoo

Advancing rare disease trials by overcoming patient recruitment challenges

Next month, clinical development and clinical operations professionals will gather and discuss the current challenges in running clinical trials for orphan drugs and rare diseases at the 3rd Annual Clinical Trials in Rare Diseases (CTRD) meeting in Princeton, New Jersey. The meeting, which will take place 17–18 September, will bring together experts from the pharmaceutical and biotech sectors to discuss, not only the obstacles and solutions to clinical trial operational issues, but also to explore the evolving landscape of clinical trials for rare diseases, with a strong emphasis on innovation, collaboration, and patient-centric approaches. At the same venue, the 3rd Annual Clinical Data Management Innovation (CDMI) will explore ways to streamline data entry and collection at trial sites, make better use of real-world evidence, and address the evolving regulatory environment around clinical data. Both meetings will run in parallel at the same venue in Princeton, New Jersey. The Clinical Trials in Rare Diseases meeting will kick off with a case study on how artificial intelligence (AI) is accelerating rare disease drug development. During the talk, Bruce Bloom, CEO of Fortuity Pharma, will map out processes for pre-IND packages, working with the US Food and Drug Administration (FDA), and explore both the challenges and successes of applying AI in such trials. At the CDMI conference, a keynote by Jeff Malavasi, Associate Director of Information Security and Data Compliance of the Cambridge, Massachusetts-based biotech Scholar Rock, will focus on the growing cybersecurity challenges created by the digital transformation of clinical trials. His talk will also provide a practical framework for adopting AI-driven security solutions, including zero-trust architectures and automated response protocols, to safeguard sensitive clinical data. Building on the theme of AI, Aamir Jaka, Global Vice President of the clinical analytics company Saama, will laterexplore how agentic AI is moving data management beyond traditional rule-based automation. Patient recruitment is a persistent challenge in rare disease research On the same day, Jamie Switzer, Associate Director of Clinical Operations at Insmed, will present a case study on strategies to keep trials on schedule while tackling the issue of patient recruitment. Earlier this month, Insmed's drug Brinsupri (brensocatib) was approved to treat non-cystic fibrosis bronchiectasis by the FDA based on results from the Phase III ASPEN (NCT04594369) and Phase II WILLOW (NCT03218917) studies. Switzer will provide practical solutions to patient recruitment problems, while a subsequent panel discussion featuring industry leads from Alexion, Insmed, Asklepion Pharmaceuticals, and BioMarin will take the conversation further to discuss innovative ways to engage patients. Patient recruitment and patient advocacy will be a recurring theme throughout the conference, with speakers sharing insights and emphasising the importance of having patient advocacy organisations as an indispensable partner to extend trial reach, co-design protocols, and foster genuine patient-centered practices. Patient centricity will also be a key theme in the CDMI meeting, where Dinesh Pillaipakkamnatt, former Director of Merck & Co, will highlight how to create a more personalised trial experience, while also considering data privacy, adoption barriers, and the safe handling of large volumes of sensitive information. Tackling operational challenges with clinical trials The second day of both meetings will commence with interactive roundtable discussions on topics such as importance of decentralising rare disease trials, strategies to overcome patient retention barriers, best practices for managing external data and addressing issues of identity, integration, and privacy while enabling patient-centric data management, across both the conferences. The patient and caregiver perspective with rare disease research will be explored with Leigh Dallow, Patient Advocate & Caregiver, sharing her experience around trial participation, discussing trial enrollment decisions, and patient burden, in the CTRD meeting. In a subsequent session, an expert from the Rare Disease Diversity Coalition will discuss the issues of inclusion and diversity in rare disease trials, focusing on underrepresented populations and ways to ensure fair access to therapies and research opportunities. In the afternoon, the focus will shift to the strategic and operational elements of rare disease drug development. In a fireside chat, Bloom and Paul Lupo of PTC Therapeutics will discuss issues such as how to select a CRO and how to work with small patient populations. Another fireside chat, led by Kinjal Patel and Janine Sampong, both with Mitsubishi Tanabe Pharma America, will examine how to accelerate timelines when working with clinical sites and propose strategies to attract attention of academic organisations, and build strong partnerships. Concurrently, the second day of the CDMI meeting will feature several sessions on successful strategies for CDM vendor selection and outsourcing models, an important update on ICH E6(R3) guidelines and its implications for clinical data management, and the implications of AI and machine learning for clinical data management. The meeting will conclude with a case study on CRO and sponsor collaboration, emphasising the importance of improving partnerships and aligning financial incentives. The 3rd Annual Clinical Trials in Rare Diseases and the 3rd Annual Clinical Data Management Innovation conferences are hosted by Arena International Events Group, a B2B events company owned by GlobalData, the parent company of Clinical Trials Arena and Pharmaceutical Technology. Click here to read the agenda for the conference for 3rd Annual Clinical Trials in Rare Diseases and the 3rd Annual Clinical Data Management Innovation. "Advancing rare disease trials by overcoming patient recruitment challenges" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

PathAI and Moffitt Cancer Center Announce Strategic Collaboration to Deploy the AISight® Dx Digital Pathology Platform and Advance AI Diagnostics
PathAI and Moffitt Cancer Center Announce Strategic Collaboration to Deploy the AISight® Dx Digital Pathology Platform and Advance AI Diagnostics

Yahoo

time6 hours ago

  • Yahoo

PathAI and Moffitt Cancer Center Announce Strategic Collaboration to Deploy the AISight® Dx Digital Pathology Platform and Advance AI Diagnostics

Partnership includes joint collaboration initiatives to improve precision medicine and accelerate innovation in cancer pathology BOSTON, Mass., and TAMPA, Fla., Aug. 21, 2025 (GLOBE NEWSWIRE) -- PathAI, a global leader in artificial intelligence and digital pathology solutions, and Moffitt Cancer Center, one of the nation's top cancer hospitals and a leader in cancer research, today announced a multi-year strategic collaboration to deploy PathAI's digital pathology platform, AISight® Dx, across Moffitt's pathology programs to transform cancer detection and innovation. AISight® Dx, is PathAI's cloud-native digital pathology image management system designed to support both laboratory workflow and translational research use cases. It combines enterprise-scale slide management, viewing, and collaboration with seamless AI integration, driving scalable pathology operational efficiencies and enhanced speed and accuracy. The partnership also establishes a framework for joint research programs, collation of real-world multimodal data, initiatives to support clinical trials and biopharma collaborations, and the co-development of next-generation AI-based diagnostics to enhance precision medicine. 'We are thrilled to partner with Moffitt Cancer Center, an institution renowned for its commitment to innovation and excellence in cancer care,' said Andy Beck, MD, PhD, CEO and Co-Founder of PathAI. 'By deploying AISight® Dx and building this strategic partnership, we're equipping Moffitt's pathologists and researchers with cutting-edge tools to support diagnosis, streamline operations, and unlock novel insights from pathology data.' 'This collaboration aligns perfectly with Moffitt's mission to contribute to the prevention and cure of cancer through transformative care, cutting-edge science and innovation,' said Karen Lu, MD, executive vice president and physician-in-chief at Moffitt Cancer Center. 'By deploying AISight® Dx into our pathology infrastructure, we're taking a significant step forward in the integration of AI-driven technology into clinical oncology, enabling faster, more accurate pathologist review. 'Adopting cutting-edge digital pathology technologies is key to driving Moffitt's vision for a true digital transformation, one that unlocks a wealth of pathology data and seamlessly integrates it with imaging and clinical insights to deliver truly personalized patient care,' said William Westra, MD, vice chair of Pathology at Moffitt Cancer Center. 'By partnering with PathAI, we're laying the groundwork for next-generation oncology research that will shape future AI-powered care models, while building on PathAI's and Moffitt's legacy of advancing cancer pathology, innovative therapies, and breakthrough diagnostics.' Together, PathAI and Moffitt Cancer Center aim to redefine the role of digital pathology and AI in cancer care, setting a precedent for how cutting-edge technologies and clinical expertise can converge to drive meaningful improvements in pathology. For more information about PathAI, or AISight Dx, please contact or visit 1AISight® is for Research Use Only in the US; AISight® Dx is FDA-cleared for primary diagnosis in the US, and is CE‑IVD–marked for primary diagnosis in the EEA, UK, and Switzerland. About PathAI PathAI is a leading provider of integrated AI and digital pathology solutions dedicated to transforming workflow and operational efficiency in pathology labs worldwide. Through innovative technologies and strategic partnerships, PathAI aims to enhance patient outcomes and drive the future of medical diagnostics. For more information, visit About Moffitt Cancer Center Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 57 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt's scientific excellence, multidisciplinary research, and robust training and education. Moffitt's expert nursing staff is recognized by the American Nurses Credentialing Center with Magnet® status, its highest distinction. For more information, call 1-888-MOFFITT (1-888-663-3488), visit and follow the momentum on Facebook, X, Instagram and YouTube. Company Contact Liz Storti Chief People Officer Media Contact Owen Blaschak LifeSci Communications oblaschak@

PathAI and Moffitt Cancer Center Announce Strategic Collaboration to Deploy the AISight® Dx Digital Pathology Platform and Advance AI Diagnostics
PathAI and Moffitt Cancer Center Announce Strategic Collaboration to Deploy the AISight® Dx Digital Pathology Platform and Advance AI Diagnostics

Associated Press

time6 hours ago

  • Associated Press

PathAI and Moffitt Cancer Center Announce Strategic Collaboration to Deploy the AISight® Dx Digital Pathology Platform and Advance AI Diagnostics

BOSTON, Mass., and TAMPA, Fla., Aug. 21, 2025 (GLOBE NEWSWIRE) -- PathAI, a global leader in artificial intelligence and digital pathology solutions, and Moffitt Cancer Center, one of the nation's top cancer hospitals and a leader in cancer research, today announced a multi-year strategic collaboration to deploy PathAI's digital pathology platform, AISight® Dx, across Moffitt's pathology programs to transform cancer detection and innovation. AISight® Dx, is PathAI's cloud-native digital pathology image management system designed to support both laboratory workflow and translational research use cases. It combines enterprise-scale slide management, viewing, and collaboration with seamless AI integration, driving scalable pathology operational efficiencies and enhanced speed and accuracy. The partnership also establishes a framework for joint research programs, collation of real-world multimodal data, initiatives to support clinical trials and biopharma collaborations, and the co-development of next-generation AI-based diagnostics to enhance precision medicine. 'We are thrilled to partner with Moffitt Cancer Center, an institution renowned for its commitment to innovation and excellence in cancer care,' said Andy Beck, MD, PhD, CEO and Co-Founder of PathAI. 'By deploying AISight ® Dx and building this strategic partnership, we're equipping Moffitt's pathologists and researchers with cutting-edge tools to support diagnosis, streamline operations, and unlock novel insights from pathology data.' 'This collaboration aligns perfectly with Moffitt's mission to contribute to the prevention and cure of cancer through transformative care, cutting-edge science and innovation,' said Karen Lu, MD, executive vice president and physician-in-chief at Moffitt Cancer Center. 'By deploying AISight® Dx into our pathology infrastructure, we're taking a significant step forward in the integration of AI-driven technology into clinical oncology, enabling faster, more accurate pathologist review. 'Adopting cutting-edge digital pathology technologies is key to driving Moffitt's vision for a true digital transformation, one that unlocks a wealth of pathology data and seamlessly integrates it with imaging and clinical insights to deliver truly personalized patient care,' said William Westra, MD, vice chair of Pathology at Moffitt Cancer Center. 'By partnering with PathAI, we're laying the groundwork for next-generation oncology research that will shape future AI-powered care models, while building on PathAI's and Moffitt's legacy of advancing cancer pathology, innovative therapies, and breakthrough diagnostics.' Together, PathAI and Moffitt Cancer Center aim to redefine the role of digital pathology and AI in cancer care, setting a precedent for how cutting-edge technologies and clinical expertise can converge to drive meaningful improvements in pathology. For more information about PathAI, or AISight Dx, please contact [email protected] or visit 1 AISight® is for Research Use Only in the US; AISight® Dx is FDA-cleared for primary diagnosis in the US, and is CE‑IVD–marked for primary diagnosis in the EEA, UK, and Switzerland. About PathAI PathAI is a leading provider of integrated AI and digital pathology solutions dedicated to transforming workflow and operational efficiency in pathology labs worldwide. Through innovative technologies and strategic partnerships, PathAI aims to enhance patient outcomes and drive the future of medical diagnostics. For more information, visit About Moffitt Cancer Center Moffitt is dedicated to one lifesaving mission: to contribute to the prevention and cure of cancer. The Tampa-based facility is one of only 57 National Cancer Institute-designated Comprehensive Cancer Centers, a distinction that recognizes Moffitt's scientific excellence, multidisciplinary research, and robust training and education. Moffitt's expert nursing staff is recognized by the American Nurses Credentialing Center with Magnet® status, its highest distinction. For more information, call 1-888-MOFFITT (1-888-663-3488), visit and follow the momentum on Facebook, X, Instagram and YouTube. Company Contact Liz Storti Chief People Officer [email protected] Media Contact Owen Blaschak LifeSci Communications [email protected]

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store